Figure 2.
Utilization of LAT substrates in patients with ASD with and without variants in LAT genes. Graphic representation of the percentage of wells containing LNAAs (tryptophan, phenylalanine, tyrosine, valine, isoleucine, and leucine) and histidine showing significantly lower levels of NADH as compared to 50 control cell lines. Black: cell lines from patients with ASD with sequence variants or abnormal expression levels in LAT genes. Grey: cell lines from patients with ASD without abnormal findings in LAT genes. The percentages are based on endpoint absorbance raw data calculated on the two cohorts collectively. See Supplemental Files 3 and 4 for more details